Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized Multicenter Study to Evaluate the Efficacy and Safety of Open-Label Dual Therapy With Oral Vonoprazan 20 mg or Double-Blind Triple Therapy With Oral Vonoprazan 20 mg Compared to Double-Blind Triple Therapy With Oral Lansoprazole 30 mg Daily in Patients With Helicobacter Pylori Infection

NCT04167670 is registered in ClinicalTrials.gov with Phathom Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04167670
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04167670 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized Multicenter Study to Evaluate the Efficacy and Safety of Open-Label Dual Therapy With Oral Vonoprazan 20 mg or Double-Blind Triple Therapy With Oral Vonoprazan 20 mg Compared to Double-Blind Triple Therapy With Oral Lansoprazole 30 mg Daily in Patients With Helicobacter Pylori Infection
Lead sponsor
Phathom Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
December 10, 2019
Completion date
March 18, 2021
Enrollment
1,046 (actual)
Sites
153

Conditions

As the registry lists them; a condition with its own page is linked.

helicobacter pylori infection